Open Access

Cells

, volume 9 , issue 2 , pages 406

Future Therapeutic Directions for Smac-Mimetics

Emma Morrish ^{1, 2}

Gabriela Brumatti ^{1, 2}

John Silke ^{1, 2}

Hide authors affiliations Show authors affiliations: 2 affiliations

Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne VIC 3052, Australia

Walter and Eliza Hall Institute of Medical Research

Royal Children's Hospital Melbourne

Department of Medical Biology, University of Melbourne, Melbourne VIC 3010, Australia |

Publication type: Journal Article

Publication date: 2020-02-11

MDPI

Cells

scimago Q1

wos Q2

SJR: 1.670

CiteScore: 10.5

Impact factor: 5.2

ISSN: 20734409

DOI: 10.3390/cells9020406

Copy DOI

PubMed ID: 32053868

General Medicine

Abstract

It is well accepted that the ability of cancer cells to circumvent the cell death program that untransformed cells are subject to helps promote tumor growth. Strategies designed to reinstate the cell death program in cancer cells have therefore been investigated for decades. Overexpression of members of the Inhibitor of APoptosis (IAP) protein family is one possible mechanism hindering the death of cancer cells. To promote cell death, drugs that mimic natural IAP antagonists, such as second mitochondria-derived activator of caspases (Smac/DIABLO) were developed. Smac-Mimetics (SMs) have entered clinical trials for hematological and solid cancers, unfortunately with variable and limited results so far. This review explores the use of SMs for the treatment of cancer, their potential to synergize with up-coming treatments and, finally, discusses the challenges and optimism facing this strategy.

Found

1 citation

Yagolovich Anne

🥼 🤝

PhD in Biological/biomedical sciences, lecturer

31 publications, 279 citations, 4 reviews

h-index: 10

Lomonosov Moscow State University

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Research interests

Apoptosis

1 citation

Chugunova Elena

🤝

DSc in Chemistry

62 publications, 532 citations, 1 review

h-index: 13

A.E. Arbuzov Institute of Organic and Physical Chemistry of the Kazan Scientific Center of the Russian Academy of Sciences

Kazan National Research Technological University

Top-30

Journals

	1 2 3 4 5 6 7
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 7, 5.93% International Journal of Molecular Sciences 7 publications, 5.93%
Cell Death and Disease	Cell Death and Disease, 7, 5.93% Cell Death and Disease 7 publications, 5.93%
Cancers	Cancers, 5, 4.24% Cancers 5 publications, 4.24%
Cell Death and Differentiation	Cell Death and Differentiation, 4, 3.39% Cell Death and Differentiation 4 publications, 3.39%
European Journal of Medicinal Chemistry	European Journal of Medicinal Chemistry, 4, 3.39% European Journal of Medicinal Chemistry 4 publications, 3.39%
Frontiers in Immunology	Frontiers in Immunology, 3, 2.54% Frontiers in Immunology 3 publications, 2.54%
Frontiers in Cell and Developmental Biology	Frontiers in Cell and Developmental Biology, 3, 2.54% Frontiers in Cell and Developmental Biology 3 publications, 2.54%
EMBO Journal	EMBO Journal, 3, 2.54% EMBO Journal 3 publications, 2.54%
Science	Science, 2, 1.69% Science 2 publications, 1.69%
Frontiers in Oncology	Frontiers in Oncology, 2, 1.69% Frontiers in Oncology 2 publications, 1.69%
Cells	Cells, 2, 1.69% Cells 2 publications, 1.69%
Biomolecules	Biomolecules, 2, 1.69% Biomolecules 2 publications, 1.69%
Scientific Reports	Scientific Reports, 2, 1.69% Scientific Reports 2 publications, 1.69%
Cellular and Molecular Life Sciences	Cellular and Molecular Life Sciences, 2, 1.69% Cellular and Molecular Life Sciences 2 publications, 1.69%
Biochemical and Biophysical Research Communications	Biochemical and Biophysical Research Communications, 2, 1.69% Biochemical and Biophysical Research Communications 2 publications, 1.69%
Seminars in Cell and Developmental Biology	Seminars in Cell and Developmental Biology, 2, 1.69% Seminars in Cell and Developmental Biology 2 publications, 1.69%
Methods in Molecular Biology	Methods in Molecular Biology, 2, 1.69% Methods in Molecular Biology 2 publications, 1.69%
EMBO Molecular Medicine	EMBO Molecular Medicine, 2, 1.69% EMBO Molecular Medicine 2 publications, 1.69%
Science advances	Science advances, 2, 1.69% Science advances 2 publications, 1.69%
Cell Metabolism	Cell Metabolism, 2, 1.69% Cell Metabolism 2 publications, 1.69%
Nature Reviews Cancer	Nature Reviews Cancer, 2, 1.69% Nature Reviews Cancer 2 publications, 1.69%
Respiration	Respiration, 1, 0.85% Respiration 1 publication, 0.85%
Oncology Reports	Oncology Reports, 1, 0.85% Oncology Reports 1 publication, 0.85%
Viruses	Viruses, 1, 0.85% Viruses 1 publication, 0.85%
Crystals	Crystals, 1, 0.85% Crystals 1 publication, 0.85%
Frontiers in Cellular and Infection Microbiology	Frontiers in Cellular and Infection Microbiology, 1, 0.85% Frontiers in Cellular and Infection Microbiology 1 publication, 0.85%
Clinical and Experimental Metastasis	Clinical and Experimental Metastasis, 1, 0.85% Clinical and Experimental Metastasis 1 publication, 0.85%
Journal of Translational Medicine	Journal of Translational Medicine, 1, 0.85% Journal of Translational Medicine 1 publication, 0.85%
iScience	iScience, 1, 0.85% iScience 1 publication, 0.85%
	1 2 3 4 5 6 7

Publishers

	5 10 15 20 25 30
Springer Nature	Springer Nature, 26, 22.03% Springer Nature 26 publications, 22.03%
Elsevier	Elsevier, 25, 21.19% Elsevier 25 publications, 21.19%
MDPI	MDPI, 20, 16.95% MDPI 20 publications, 16.95%
Frontiers Media S.A.	Frontiers Media S.A., 9, 7.63% Frontiers Media S.A. 9 publications, 7.63%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 5, 4.24% American Association for the Advancement of Science (AAAS) 5 publications, 4.24%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 5, 4.24% Cold Spring Harbor Laboratory 5 publications, 4.24%
Wiley	Wiley, 4, 3.39% Wiley 4 publications, 3.39%
European Molecular Biology Organization	European Molecular Biology Organization, 4, 3.39% European Molecular Biology Organization 4 publications, 3.39%
Spandidos Publications	Spandidos Publications, 2, 1.69% Spandidos Publications 2 publications, 1.69%
American Chemical Society (ACS)	American Chemical Society (ACS), 2, 1.69% American Chemical Society (ACS) 2 publications, 1.69%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 2, 1.69% American Association for Cancer Research (AACR) 2 publications, 1.69%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 2, 1.69% Bentham Science Publishers Ltd. 2 publications, 1.69%
S. Karger AG	S. Karger AG, 1, 0.85% S. Karger AG 1 publication, 0.85%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 0.85% Public Library of Science (PLoS) 1 publication, 0.85%
Hindawi Limited	Hindawi Limited, 1, 0.85% Hindawi Limited 1 publication, 0.85%
Zhejiang University Press	Zhejiang University Press, 1, 0.85% Zhejiang University Press 1 publication, 0.85%
BMJ	BMJ, 1, 0.85% BMJ 1 publication, 0.85%
AME Publishing Company	AME Publishing Company, 1, 0.85% AME Publishing Company 1 publication, 0.85%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 1, 0.85% Ovid Technologies (Wolters Kluwer Health) 1 publication, 0.85%
Federation of American Societies for Experimental Biology (FASEB)	Federation of American Societies for Experimental Biology (FASEB), 1, 0.85% Federation of American Societies for Experimental Biology (FASEB) 1 publication, 0.85%
Rockefeller University Press	Rockefeller University Press, 1, 0.85% Rockefeller University Press 1 publication, 0.85%
American Society of Hematology	American Society of Hematology, 1, 0.85% American Society of Hematology 1 publication, 0.85%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 0.85% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 0.85%
American Society for Clinical Investigation	American Society for Clinical Investigation, 1, 0.85% American Society for Clinical Investigation 1 publication, 0.85%
	5 10 15 20 25 30

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

118

Cite this

GOST |

Cite this

GOST Copy

Morrish E. et al. Future Therapeutic Directions for Smac-Mimetics // Cells. 2020. Vol. 9. No. 2. p. 406.

GOST all authors (up to 50) Copy

Morrish E., Brumatti G., Silke J. Future Therapeutic Directions for Smac-Mimetics // Cells. 2020. Vol. 9. No. 2. p. 406.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.3390/cells9020406

UR - https://doi.org/10.3390/cells9020406

TI - Future Therapeutic Directions for Smac-Mimetics

T2 - Cells

AU - Morrish, Emma

AU - Brumatti, Gabriela

AU - Silke, John

PY - 2020

DA - 2020/02/11

PB - MDPI

SP - 406

IS - 2

VL - 9

PMID - 32053868

SN - 2073-4409

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Morrish,

author = {Emma Morrish and Gabriela Brumatti and John Silke},

title = {Future Therapeutic Directions for Smac-Mimetics},

journal = {Cells},

year = {2020},

volume = {9},

publisher = {MDPI},

month = {feb},

url = {https://doi.org/10.3390/cells9020406},

number = {2},

pages = {406},

doi = {10.3390/cells9020406}

}

MLA

Cite this

MLA Copy

Morrish, Emma, et al. “Future Therapeutic Directions for Smac-Mimetics.” Cells, vol. 9, no. 2, Feb. 2020, p. 406. https://doi.org/10.3390/cells9020406.

Publisher

MDPI

Journal

Cells

scimago Q1

wos Q2

SJR

1.670

CiteScore

10.5

Impact factor

5.2

ISSN

20734409 (Print, Electronic)